Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BNTX · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortBioNTech SE is loss-making, generates cash and holds more cash than debt, with revenue growing (+4.3% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -49.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -39.6% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -5.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -5.4% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 7.54× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.06× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -20.13× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 13.71 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 9.8% | 59/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 1727.5% | 0/100 |
| Operating margin volatility | 62.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -45.1% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 18,977 | 17,311 | 3,819 | 2,751 | 2,870 |
| Cost of revenue | 2,912 | 2,995 | 600 | 541 | 642 |
| Gross profit | 16,065 | 14,316 | 3,219 | 2,210 | 2,228 |
| Research & development | 949 | 1,537 | 1,783 | 2,254 | 2,105 |
| Operating income | 15,284 | 12,643 | 690 | (1,314) | (1,405) |
| Interest expense | 305 | 19 | 24 | 27 | 70 |
| Pre-tax income | 15,046 | 12,954 | 1,186 | (678) | (1,051) |
| Income tax | 4,754 | 3,520 | 256 | (12) | 85 |
| Net income | 10,293 | 9,434 | 930 | (665) | (1,136) |
| Diluted EPS | €39.63 | €37.77 | €3.83 | −€2.77 | −€4.70 |
| Diluted shares (millions) | 260 | 250 | 243 | 240 | 242 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
13.71 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Dec 31, 2025 · Data updated Mar 10, 2026